360° SearchNetwork Hot Spots Trends Time Series

INLYTA

Type: Product

Name: INLYTA

First reported May 20 2013 - Updated 10 hours ago - 1 reports

Pfizer halts study of non-Hodgkin's lymphoma drug

Drugmaker Pfizer Inc. has halted a late-stage study of an experimental cancer compound being tested in patients with a certain form of non-Hodgkin's lymphoma, because an interim analysis showed the drug wasn't helping patients live longer.Pfizer said ... [Published Barchart - May 20 2013]

Entities: Pfizer Inc, Cancer, Patient, rituximab, Drugs

First reported May 18 2013 - Updated May 18 2013 - 2 reports

Will ASCO Unlock Big Value in This Cancer Drug Class?

It's a 100% FREE Motley Fool service...There's little denying that Roche's (NASDAQOTH: RHHBY ) cancer wonder drug Avastin has been a godsend to cancer patients and investors alike.Avastin -- which the Food and Drug Administration has approved to treat ... [Published Motley Fool Discussion Boards - May 18 2013]

Entities: Avastin, Monoclonal Antibodies, Metastatic

First reported May 18 2013 - Updated May 18 2013 - 1 reports

erlotinib

Dermatologic Adverse Events Associated With Targeted Therapies

Novel cancer therapies have brought about unprecedented improvements in survival along with decreased hematopoietic toxicities, when compared with cytotoxic chemotherapy. Therefore, other components of the cancer experience have come forward, such as ... [Published Cancernetwork.com - May 18 2013]

Entities: Exanthema subitum, Vemurafenib, Ipilimumab, erlotinib, Patient

First reported May 03 2013 - Updated May 03 2013 - 1 reports

FDA Food & Drug Administration

Searching for the wrong miracles

The US pharmaceutical landscape has changed rapidly and radically over the past decade with dire consequences. Companies have exited en masse from research in traditional disease areas, plunging headfirst into cancer research. The result: Were getting ... [Published New York Post - May 03 2013]

Entities: Antibiotic, Cancer, Drugs, FDA Food & Drug Administration

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Lipitor

Pfizer sales down 9% but pleased with pipeline progress

Pfizer has cut its earnings forecast for 2012 after posting disappointing sales for the first quarter, hit by loss of exclusivity on the cholesterol drug Lipitor and a weak performance from the pneumococcal disease vaccine Prevnar 13.Net income came in ... [Published Pharma Times - May 01 2013]

Entities: Pfizer Inc, Lipitor, Prevnar, Enbrel, Celebrex

First reported Mar 28 2013 - Updated Mar 28 2013 - 3 reports

Pfizer Inc

Xalkori And Inlyta NICE Pans Two Pfizer Oncology Drugs In Two Days

Home » Blogs » Xalkori And Inlyta: NICE Pans Two Pfizer Oncology Drugs In Two DaysRelated Biotechnology, Pharmaceutical and Healthcare NewsBritain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma ... [Published BioPortfolio - Mar 28 2013]

Entities: INLYTA, Xalkori, Pfizer Inc, Oncology

First reported Mar 28 2013 - Updated Mar 28 2013 - 1 reports

Axitinib

NICE issues final draft guidance on a new kidney cancer drug

NICE, the healthcare guidance body, has issued final draft guidance not recommending axitinib (Inlyta, Pfizer) for the treatment of advanced kidney cancer. ... [Published NICE | National Institute for Health and Clinic ... - Mar 28 2013]

Entities: kidney cancer, antineoplastic, Axitinib, INLYTA

First reported Feb 22 2013 - Updated Feb 22 2013 - 1 reports

INLYTA (Axitinib) Tablet, Film Coated [Pfizer Laboratories Div Pfizer Inc]

Updated Date: Feb 22, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - Feb 22 2013]

Entities: Pfizer Inc, Axitinib, INLYTA

First reported Feb 18 2013 - Updated Feb 18 2013 - 1 reports

Inlyta Falls Short in Kidney Cancer

ORLANDO (MedPage Today) -- Patients with metastatic renal cell carcinoma had improved progression-free survival when treated initially with axitinib (Inlyta) instead of a slightly older multikinase inhibitor, although the results did not meet parameters ... [Published MedPageToday.com - medical news plus CME for ph ... - Feb 18 2013]

Entities: INLYTA, kidney cancer, Axitinib, renal cell carcinoma

First reported Jan 10 2013 - Updated Jan 10 2013 - 1 reports

Coming In Friday's "The Pink Sheet" DAILY Germany Gives Thumbs Up To Pfizer's Inlyta

Pfizer’s kidney cancer drug Inlyta scrapes through the German added value assessment process but Almirall’s COPD product Eklira gets a “thumbs down”, showing that comparator selection is not the only deciding factor in the process. Original Article ... [Published BioPortfolio - Jan 10 2013]

Entities: INLYTA, Pfizer Inc, Germany, Almirall SA, kidney cancer

First reported Jan 09 2013 - Updated Jan 09 2013 - 1 reports

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of US drug behemoth Pfizer's (NYSE: PFE) kidney cancer drug Inlyta (axitinib) under the Act on the Reform of the Market for Medicinal Products (AMNO.. ... [Published BioPortfolio - Jan 09 2013]

Entities: INLYTA, Pfizer Inc, IQWiG, Drugs

First reported Dec 12 2012 - Updated Dec 12 2012 - 1 reports

In NICEland Nexavar does not exist so Pfizer cant compare it with Inlyta

NICE, the health technology appraisal body for England and Wales, has declined to recommend Pfizer's Inlyta (axitinib) for second line kidney cancer because Pfizer compared it with Bayer's Nexavar (sorafenib) which NICE already..... Original Article ... [Published BioPortfolio - Dec 12 2012]

Entities: INLYTA, Nexavar, Pfizer Inc

Quotes

"We are working to better understand the findings from this review to determine if there are any patterns of outcome that may help us gain greater understanding of the potential effect of inotuzumab ozogamicin in specific patient populations" Dr. Mace Rothenberg, head of clinical development and medical affairs for Pfizer's cancer business, said in a statement

Pfizer halts study of non-Hodgkin's lymphoma drug [Published Barchart - May 20 2013]

...discovered and developed 10 approved drugs representing over $5 billion in 2012 sales," said Jonathan Lim, M D , chairman and CEO of Ignyta. "Actagene’s R&D team complements Ignyta’s existing team, platform and capabilities, such as whole genome methylation analysis, next generation sequencing, Methylome™ database, and bioinformatics expertise. This transaction reshapes us into a seamless Rx/Dx company pursuing a significant growth area of patient stratification and targeted drug discovery and development for cancer patients."

Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine [Published Business Wire - May 20 2013]

...said Kevan Shokat, Ph D , Chair of the Department of Cellular and Molecular Pharmacology at UC San Francisco (UCSF) and a co-founder of eFFECTOR. "By addressing an effector mechanism required by many oncogenes, including previously undruggable targets, selective translation regulators have the potential to treat multiple tumor types and may confer benefits beyond what has been observed clinically with inhibitors of single oncogenic targets."

eFFECTOR Therapeutics Raises $45 Million in Series A Financing [Published FinanzNachrichten.de - May 20 2013]

More From BioPortfolio on "Aveo Screwed Up but Its Kidney CancerCancer Drug Is Real"

Aveo Screwed Up but Its Kidney Cancer Drug Is Real [Published BioPortfolio - May 15 2013]

More Content

sort by: Date \| Relevance
Ignyta Announces Acquisition of Actagene Oncolo... [Published BioSpace - 11 hours ago]
eFFECTOR Therapeutics Raises $45 Million Series A [Published PE Hub News - 20 hours ago]
Pfizer halts study of non-Hodgkin's lymphoma drug [Published Barchart - May 20 2013]
Ignyta Announces Acquisition of Actagene Oncolo... [Published Business Wire - May 20 2013]
eFFECTOR Therapeutics Raises $45 Million in Ser... [Published FinanzNachrichten.de - May 20 2013]
Will ASCO Unlock Big Value in This Cancer Drug ... [Published Motley Fool Discussion Boards - May 18 2013]
Will ASCO Unlock Big Value in This Cancer Drug ... [Published EquityJungle - v0.1 - May 18 2013]
Dermatologic Adverse Events Associated With Tar... [Published Cancernetwork.com - May 18 2013]
Aveo Screwed Up but Its Kidney Cancer Drug Is Real [Published BioPortfolio - May 15 2013]
1 Casino, 1 Biotech And 1 Sofware Stock With Re... [Published Seeking Alpha - May 09 2013]
Searching for the wrong miracles [Published New York Post - May 03 2013]
Patent Expiries Hit Pfizer’s Results But New Dr... [Published Trefis - May 03 2013]
Fight Cancer, Save Lives With These Stocks [Published Nasdaq - May 01 2013]
Fight Cancer, Save Lives With These Stocks [Published EquityJungle - v0.1 - May 01 2013]
Pfizer sales down 9% but pleased with pipeline ... [Published Pharma Times - May 01 2013]
3rd UPDATE: Pfizer 1st-Quarter Profit, Sales Mi... [Published Nasdaq - Apr 30 2013]
Aveoâs Stock Plunges As Day of Reckoning Nears ... [Published Xconomy - Apr 30 2013]
Pfizer's CEO Discusses Q1 2013 Results - Earnin... [Published Seeking Alpha - Apr 30 2013]
Buy These Patent-Cliff Proof Stocks [Published Motley Fool - Apr 29 2013]
Earnings Preview: Pfizer to report Q1 results [Published Barchart - Apr 26 2013]
2 Biotechs And A Grocery Store With Recent Inte... [Published Seeking Alpha - Apr 14 2013]
Xalkori And Inlyta NICE Pans Two Pfizer Oncolog... [Published BioPortfolio - Mar 28 2013]
Pfizer gets new rebuff from UK cost body for ca... [Published News from Kidney Cancer Association - Mar 28 2013]
NICE denies NHS use of Pfizer's Inlyta for pati... [Published BioPortfolio - Mar 28 2013]
Research and Markets: Inlyta (Renal Cell Carcin... [Published Business Wire Health News - Mar 28 2013]
NICE issues final draft guidance on a new kidne... [Published NICE \| National Institute for Health and Clinic ... - Mar 28 2013]
INLYTA (Axitinib) Tablet, Film Coated [Pfizer L... [Published DailyMed Drug Label Updates for the last seven ... - Feb 22 2013]
Inlyta Falls Short in Kidney Cancer [Published MedPageToday.com - medical news plus CME for ph ... - Feb 18 2013]
Acceleron begins phase II study of Dalantercept... [Published PharmaBiz - Feb 07 2013]
Acceleron Initiates Phase 2 Study of Dalanterce... [Published EON Health & Medicine - Feb 05 2013]

Blogs

sort by: Date \| Relevance
Will ASCO Unlock Big Value in This Cancer Drug ... [Published EquityJungle - v0.1 - May 18 2013] Filed under: Investing There's little denying that Roche 's cancer wonder drug Avastin has been a godsend to cancer patients and investors alike. Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer ...
Fight Cancer, Save Lives With These Stocks [Published EquityJungle - v0.1 - May 01 2013] I recently heard from an old friend. He told me of his battle with colon cancer. His doctors had given him a 30% chance of surviving, but thanks a new generation of powerful anti-cancer drugs, his cancer has been in remission for nearly five years ...
Pfizer gets new rebuff from UK cost body for ca... [Published News from Kidney Cancer Association - Mar 28 2013] Pfizer suffered a second rejection in two days from Britain's health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service. 03/28/2013 ...
NICE issues final draft guidance on a new kidne... [Published NICE \| National Institute for Health and Clinic ... - Mar 28 2013] NICE, the healthcare guidance body, has issued final draft guidance not recommending axitinib (Inlyta, Pfizer) for the treatment of advanced kidney cancer. ...
INLYTA (Axitinib) Tablet, Film Coated [Pfizer L... [Published DailyMed Drug Label Updates for the last seven ... - Feb 22 2013] Updated Date: Feb 22, 2013 EST ...

Press Releases

sort by: Date \| Relevance
Ignyta Announces Acquisition of Actagene Oncolo... [Published Business Wire - May 20 2013]
Research and Markets: Inlyta (Renal Cell Carcin... [Published Business Wire Health News - Mar 28 2013]
Acceleron Initiates Phase 2 Study of Dalanterce... [Published EON Health & Medicine - Feb 05 2013]
Acceleron Initiates Phase 2 Study of Dalanterce... [Published Business Wire Health News - Feb 05 2013]